INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 129 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $370,000 | -28.0% | 103,038 | 0.0% | 0.13% | -21.8% |
| Q4 2021 | $514,000 | -42.1% | 103,038 | -17.9% | 0.16% | -42.7% |
| Q3 2021 | $887,000 | -29.3% | 125,466 | -7.4% | 0.29% | -30.9% |
| Q2 2021 | $1,255,000 | +3.7% | 135,466 | +3.8% | 0.42% | -3.5% |
| Q1 2021 | $1,210,000 | +37.3% | 130,466 | +31.1% | 0.43% | +12.8% |
| Q4 2020 | $881,000 | -36.7% | 99,496 | -17.0% | 0.38% | -44.1% |
| Q3 2020 | $1,391,000 | +28.3% | 119,914 | +197.9% | 0.68% | +7.0% |
| Q2 2020 | $1,084,000 | -36.2% | 40,251 | -82.4% | 0.64% | -48.4% |
| Q1 2020 | $1,698,000 | -9.9% | 228,260 | -60.0% | 1.24% | -25.9% |
| Q4 2019 | $1,884,000 | +47.3% | 570,800 | -8.3% | 1.67% | +47.4% |
| Q3 2019 | $1,279,000 | -33.4% | 622,300 | -4.1% | 1.14% | -26.9% |
| Q2 2019 | $1,920,000 | -60.6% | 648,800 | -49.1% | 1.55% | -26.7% |
| Q1 2019 | $4,877,000 | +109.9% | 1,273,500 | +119.2% | 2.12% | -4.2% |
| Q4 2018 | $2,324,000 | – | 581,100 | – | 2.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Affinity Asset Advisors, LLC | 200,000 | $998,000 | 0.36% |
| Green Alpha Advisors, LLC | 72,647 | $363,000 | 0.24% |
| Skaana Management L.P. | 227,851 | $1,137,000 | 0.18% |
| SEVEN EIGHT CAPITAL, LP | 196,351 | $980,000 | 0.18% |
| Defender Capital, LLC. | 103,038 | $514,000 | 0.16% |
| Skaana Management L.P. | 206,300 | $1,029,000 | 0.16% |
| WASATCH ADVISORS LP | 4,926,125 | $24,581,000 | 0.10% |
| Parametrica Management Ltd | 16,183 | $81,000 | 0.08% |
| Cedar Brook Financial Partners, LLC | 54,500 | $272,000 | 0.07% |
| Hennion & Walsh Asset Management, Inc. | 274,703 | $1,371,000 | 0.07% |